Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.63 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481969 | 0.92 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1KCNH2CYP2C9PDE5A | |
| SCHEMBL14481714 | 0.92 | GUCY1A1 (0.57) | GUCY1A1GUCY1B1KCNH2PDE5A | |
| SCHEMBL2521119 | 0.91 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KCNH2CYP2C9PDE5A | |
| SCHEMBL14549789 | 0.91 | GUCY1A1 (0.77) | GUCY1A1GUCY1B1KCNH2CYP2C9PDE5A | |
| SCHEMBL14549816 | 0.90 | GUCY1A1 (0.67) | GUCY1A1GUCY1B1KCNH2CYP2C9 | |
| SCHEMBL14549824 | 0.90 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1KCNH2CYP2C9PDE5A | |
| SCHEMBL14481987 | 0.88 | GUCY1A1 (0.69) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL14481690 | 0.88 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1KCNH2CYP2C9PDE5A | |
| SCHEMBL14482421 | 0.87 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1KCNH2PDE5A | |
| SCHEMBL2508215 | 0.86 | GUCY1A1 (0.82) | GUCY1A1GUCY1B1KCNH2CYP2C9PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-2549875-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-01-30 | — | — | EP | claimed |
| US-20130012511-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | claimed |
| US-9284301-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| EP-2549875-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012511-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012511-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3B, PDE3A, GUCY1B1 | GUCY1A1 5/4885GUCY1B1 3/4885KCNH2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.